Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
复制标题
非小细胞肺癌 HER2 插入患者的临床病理特征
DOI：
10.1245/s10434-015-5044-8
复制
发表时间：
2017-01-01
影响因子：
3.7
通讯作者：
Chen, Haiquan
中科院分区：
文献类型：
--
作者：
Bu, Shi;Wang, Rui;Chen, Haiquan
研究背景人表皮生长因子受体2（human epidermal growth factor receptor-2，HER 2）基因在非小细胞肺癌（non-small cell lung cancer，NSCLC）中有表达。为了帮助识别和治疗这些患者，我们调查的频率，临床病理特征，和临床结果的NSCLC患者有或没有HER 2 insertions.MethodsThe突变状态的HER 2（外显子19-20）基因进行了评估，在一个队列的1875例NSCLC患者。还分析了所有患者的EGFR、KRAS、BRAF、ALK、RET和ROS 1突变。临床特征，包括年龄，性别，吸烟状况，阶段，组织学，肿瘤大小，分化，总生存率，和无复发survival.ResultsAmong 1875 NSCLC检查，35（1.9%）是HER 2插入。与HER 2插入阴性组相比，HER 2插入患者更可能从不吸烟（97.1%，34/35例，P< 0.001），与女性显著相关（91.4%，32/35例，P< 0.001），腺癌（91.4%，32/35例患者，P= 0.01），并且倾向于不超过60岁结论HER 2基因插入可作为非小细胞肺癌的一个独立亚型，在女性、非吸烟者和腺癌中的患病率较高。HER 2应在肺癌的临床基因分型，因此患者可能受益于HER 2靶向治疗。
BackgroundThe human epidermal growth factor receptor-2 (HER2) genes have been described in a subset of non-small cell lung cancer (NSCLC). To help identify and treat these patients, we investigated the frequency, clinicopathologic characteristics, and clinical outcomes of patients who had NSCLC with or without HER2 insertions.MethodsThe mutational status of the HER2 (exons 19–20) gene was assessed in a cohort of 1875 patients with NSCLC. All patients were also analyzed for mutations in EGFR, KRAS, BRAF, ALK, RET, and ROS1. Clinical characteristics, including age, sex, smoking status, stage, histology, tumor size, differentiation, overall survival, and relapse-free survival, were collected.ResultsAmong 1875 NSCLCs examined, 35 (1.9 %) were HER2 insertion. Compared with the HER2 insertion-negative group, patients with HER2 insertions were more likely to be never smokers (97.1 %, 34/35 patients,P< 0.001), significantly associated with female (91.4 %, 32/35 patients,P< 0.001), adenocarcinoma (91.4 %, 32/35 patients,P= 0.01), and with a tendency to be no more than 60 years of age (71.4 %, 25/35 patients,P= 0.051).ConclusionsHER2 insertion could define a distinct subset of NSCLC, which had a higher prevalence among females, nonsmokers, and adenocarcinoma. HER2 should be in the clinical genotyping of lung cancer, so patients may benefit from HER2-targeted therapy.